JP2002515423A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002515423A5 JP2002515423A5 JP2000549222A JP2000549222A JP2002515423A5 JP 2002515423 A5 JP2002515423 A5 JP 2002515423A5 JP 2000549222 A JP2000549222 A JP 2000549222A JP 2000549222 A JP2000549222 A JP 2000549222A JP 2002515423 A5 JP2002515423 A5 JP 2002515423A5
- Authority
- JP
- Japan
- Prior art keywords
- coating
- water
- active ingredient
- polymer
- pharmaceutical form
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000011248 coating agent Substances 0.000 description 15
- 238000000576 coating method Methods 0.000 description 15
- 239000004480 active ingredient Substances 0.000 description 13
- 229920000642 polymer Polymers 0.000 description 10
- 229940079593 drug Drugs 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 229920003176 water-insoluble polymer Polymers 0.000 description 7
- 229920003169 water-soluble polymer Polymers 0.000 description 7
- 230000007935 neutral effect Effects 0.000 description 6
- 230000035699 permeability Effects 0.000 description 5
- 239000002245 particle Substances 0.000 description 4
- 230000037406 food intake Effects 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 239000004014 plasticizer Substances 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 238000005507 spraying Methods 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000000043 antiallergic agent Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 description 1
- 229960004166 diltiazem Drugs 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000002788 histamine agent Substances 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 229940071676 hydroxypropylcellulose Drugs 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229960001722 verapamil Drugs 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR98/06384 | 1998-05-20 | ||
| FR9806384A FR2778848B1 (fr) | 1998-05-20 | 1998-05-20 | Forme pharmaceutique multiparticulaire a liberation programmee et pulsee et son procede de preparation |
| PCT/FR1999/001201 WO1999059557A1 (fr) | 1998-05-20 | 1999-05-20 | Forme pharmaceutique multiparticulaire a liberation programmee et pulsee et son procede de preparation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2002515423A JP2002515423A (ja) | 2002-05-28 |
| JP2002515423A5 true JP2002515423A5 (enExample) | 2009-12-17 |
Family
ID=9526556
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000549222A Pending JP2002515423A (ja) | 1998-05-20 | 1999-05-20 | プログラム放出性及びパルス放出性の多微粒子薬剤形態、及びその調製方法 |
Country Status (24)
| Country | Link |
|---|---|
| EP (1) | EP1077687B1 (enExample) |
| JP (1) | JP2002515423A (enExample) |
| KR (1) | KR100583065B1 (enExample) |
| CN (1) | CN1186014C (enExample) |
| AT (1) | ATE214598T1 (enExample) |
| AU (1) | AU758299B2 (enExample) |
| BG (1) | BG64764B1 (enExample) |
| BR (1) | BR9910606A (enExample) |
| CA (1) | CA2333188C (enExample) |
| DE (1) | DE69901062T2 (enExample) |
| DK (1) | DK1077687T3 (enExample) |
| ES (1) | ES2173739T3 (enExample) |
| FR (1) | FR2778848B1 (enExample) |
| GE (1) | GEP20022750B (enExample) |
| HU (1) | HU224193B1 (enExample) |
| IL (1) | IL139774A (enExample) |
| MX (1) | MXPA00011364A (enExample) |
| NO (1) | NO330501B1 (enExample) |
| NZ (1) | NZ508392A (enExample) |
| PL (1) | PL192950B1 (enExample) |
| PT (1) | PT1077687E (enExample) |
| TR (1) | TR200100107T2 (enExample) |
| WO (1) | WO1999059557A1 (enExample) |
| ZA (1) | ZA200006768B (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8071128B2 (en) | 1996-06-14 | 2011-12-06 | Kyowa Hakko Kirin Co., Ltd. | Intrabuccally rapidly disintegrating tablet and a production method of the tablets |
| US9358214B2 (en) | 2001-10-04 | 2016-06-07 | Adare Pharmaceuticals, Inc. | Timed, sustained release systems for propranolol |
| US8367111B2 (en) | 2002-12-31 | 2013-02-05 | Aptalis Pharmatech, Inc. | Extended release dosage forms of propranolol hydrochloride |
| US8802139B2 (en) | 2003-06-26 | 2014-08-12 | Intellipharmaceutics Corp. | Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient |
| US10624858B2 (en) | 2004-08-23 | 2020-04-21 | Intellipharmaceutics Corp | Controlled release composition using transition coating, and method of preparing same |
| US8747895B2 (en) | 2004-09-13 | 2014-06-10 | Aptalis Pharmatech, Inc. | Orally disintegrating tablets of atomoxetine |
| US9884014B2 (en) | 2004-10-12 | 2018-02-06 | Adare Pharmaceuticals, Inc. | Taste-masked pharmaceutical compositions |
| US20060105039A1 (en) | 2004-10-21 | 2006-05-18 | Jin-Wang Lai | Taste-masked pharmaceutical compositions with gastrosoluble pore-formers |
| AU2013273835B2 (en) * | 2005-05-02 | 2016-07-07 | Adare Pharmaceuticals, Inc. | Timed, pulsatile release systems |
| US9161918B2 (en) * | 2005-05-02 | 2015-10-20 | Adare Pharmaceuticals, Inc. | Timed, pulsatile release systems |
| US10064828B1 (en) | 2005-12-23 | 2018-09-04 | Intellipharmaceutics Corp. | Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems |
| US10960077B2 (en) | 2006-05-12 | 2021-03-30 | Intellipharmaceutics Corp. | Abuse and alcohol resistant drug composition |
| WO2008136016A1 (en) * | 2007-05-08 | 2008-11-13 | Medreich Limited | A stable controlled release oral solid dosage form composition and a process thereof |
| NZ600256A (en) | 2009-12-02 | 2014-05-30 | Aptalis Pharma Ltd | Fexofenadine microcapsules and compositions containing them |
| FR2999432B1 (fr) | 2012-12-17 | 2014-12-12 | Ethypharm Sa | Comprimes orodispersibles obtenus par compression moulage |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2558396B2 (ja) * | 1990-06-28 | 1996-11-27 | 田辺製薬株式会社 | 放出制御型製剤 |
| US5567441A (en) * | 1995-03-24 | 1996-10-22 | Andrx Pharmaceuticals Inc. | Diltiazem controlled release formulation |
| FR2754710B1 (fr) * | 1996-10-22 | 1998-12-31 | Prographarm Lab | Procede de preparation d'une forme pharmaceutique multiparticulaire a liberation controlee plurisequentielle |
-
1998
- 1998-05-20 FR FR9806384A patent/FR2778848B1/fr not_active Expired - Lifetime
-
1999
- 1999-05-20 AU AU38302/99A patent/AU758299B2/en not_active Expired
- 1999-05-20 WO PCT/FR1999/001201 patent/WO1999059557A1/fr not_active Ceased
- 1999-05-20 DK DK99920897T patent/DK1077687T3/da active
- 1999-05-20 MX MXPA00011364A patent/MXPA00011364A/es active IP Right Grant
- 1999-05-20 HU HU0102027A patent/HU224193B1/hu active IP Right Grant
- 1999-05-20 IL IL13977499A patent/IL139774A/xx not_active IP Right Cessation
- 1999-05-20 JP JP2000549222A patent/JP2002515423A/ja active Pending
- 1999-05-20 PT PT99920897T patent/PT1077687E/pt unknown
- 1999-05-20 NZ NZ508392A patent/NZ508392A/xx not_active IP Right Cessation
- 1999-05-20 DE DE69901062T patent/DE69901062T2/de not_active Expired - Lifetime
- 1999-05-20 ES ES99920897T patent/ES2173739T3/es not_active Expired - Lifetime
- 1999-05-20 EP EP99920897A patent/EP1077687B1/fr not_active Expired - Lifetime
- 1999-05-20 AT AT99920897T patent/ATE214598T1/de active
- 1999-05-20 TR TR2001/00107T patent/TR200100107T2/xx unknown
- 1999-05-20 PL PL344314A patent/PL192950B1/pl unknown
- 1999-05-20 BR BR9910606-0A patent/BR9910606A/pt not_active Application Discontinuation
- 1999-05-20 CA CA2333188A patent/CA2333188C/fr not_active Expired - Lifetime
- 1999-05-20 KR KR1020007013020A patent/KR100583065B1/ko not_active Expired - Fee Related
- 1999-05-20 CN CNB998074322A patent/CN1186014C/zh not_active Expired - Lifetime
- 1999-05-20 GE GEAP19995632A patent/GEP20022750B/en unknown
-
2000
- 2000-11-17 NO NO20005838A patent/NO330501B1/no not_active IP Right Cessation
- 2000-11-17 BG BG104963A patent/BG64764B1/bg unknown
- 2000-11-20 ZA ZA200006768A patent/ZA200006768B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2002515423A5 (enExample) | ||
| CA2349696C (en) | Controlled release formulation for water soluble drugs | |
| JP5204847B2 (ja) | エタノールの影響に対して耐性を有するｐｈ依存性制御放出医薬オピオイド組成物 | |
| AU760006B2 (en) | Method for making granules with masked taste and instant release of the active particle | |
| JP3509105B2 (ja) | 活性物質をポリマーで被覆したマイクロカプセルの製法と特にこの方法で得られる新規マイクロカプセル | |
| RU2372893C2 (ru) | Содержащий фармацевтический агент состав с покрытием | |
| EP1682094A2 (de) | Mehrschichtige arzneiform mit einer die abgabe einer modulatorischen substanz beeinflussenden matrix | |
| JP3987282B2 (ja) | 粒状化結晶性イブプロフェンで被覆した粒子 | |
| JPH0411254B2 (enExample) | ||
| JPH04501428A (ja) | ｐＨ制御膜コーチングを有する徐放性医薬製剤 | |
| EP1613333A1 (en) | Oral extended release compressed tablets of multiparticulates | |
| JP4234427B2 (ja) | 活性成分をベースとする微小顆粒およびその製造方法 | |
| KR20030024820A (ko) | Ｓ자형 조절 방출 형태를 나타내는 엘레트립탄의 미립자조성물 | |
| JP2002515423A (ja) | プログラム放出性及びパルス放出性の多微粒子薬剤形態、及びその調製方法 | |
| CN1956707B (zh) | 包含n-(2-(2-苯二酰亚氨基乙氧基)-乙酰基)-l-丙氨酰基-d-谷氨酸(lk-423)的耐胃酸的药物剂型 | |
| Bando et al. | Relationship between drug dissolution and leaching of plasticizer for pellets coated with an aqueous Eudragit® S100: L100 dispersion | |
| JPH07112932A (ja) | 徐放性医薬製剤 | |
| EP0640341A1 (en) | Sustained release pharmaceutical composition and process for producing same | |
| CN102895195A (zh) | 一种5-氟尿嘧啶分子表面印迹微球制备方法 | |
| JPH0774151B2 (ja) | 薬物の好ましくない官能的性質を隠蔽した散剤の製造方法 | |
| WO2001051031A3 (en) | Enteric coated pharmaceutical formulation | |
| JP2007509844A5 (enExample) | ||
| JP2003321515A (ja) | 胆汁酸吸着性ポリマー及びコレステロール低下剤 | |
| EP1686974A1 (en) | Extended release dosage forms of bupropion hydrochloride | |
| KR20080058041A (ko) | 인다파미드가 함유된 서방형 펠렛 |